Effect of 5-LOX/COX-2 common inhibitor DHDMBF30 on pancreatic cancer cell Capan2.
OBJECTIVE
To study the effect of 5-lipoxygenase/cyclooxygenase-2 (5-LOX/COX-2) dual inhibitor 7-tert-butyl-2, 3-dihydro-3, 3-dimethyl substituted dihydrofuran 30 (DHDMBF30) on proliferation and apoptosis of the pancreatic cancer cell line Capan-2 and the effect of DHDMBF30 on human pancreatic cancer in a nude mouse model.


METHODS
Investigate the effect of 5-LOX/COX-2 dual inhibitor DHDMBF30 on proliferation and apoptosis of the pancreatic cancer cell line Capan-2 by RT-PCR, MTT assay, FCM and electron microscope. Cell line Capan-2 was inoculated percutaneously on the outer thigh of 12 nude mice. The VEGF mRNA of transplantation tumor was detected by RT-PCR.


RESULTS
DHDMBF30 inhibits the proliferation of cell line Capan2, reduces the expression of 5-LOX, COX-2 and VEGF. After Capan2 was treated with DHDMBF30, we found that the apoptosis peak of the experimental group was significantly higher than that of the contrast group (3.08 +/- 1.89 vs 27.67 +/- 0.52, P < 0.001). The tumor weight of the DHDMBF30 group was significantly lower than PBS control groups (1.35 +/- 0.47 vs 2.92 +/- 0.73, P < 0.01). Expression of VEGF in the DHDMBF30 group was significantly decreased.


CONCLUSIONS
DHDMBF30 inhibits the proliferation of the pancreatic cell line Capan2, and induces apoptosis and inhibits the growth of pancreatic cancer in nude mice.
Zhang
Bo
B
Shandong Tumor Hospital, Jinan 250117, Shandong Province, China.
Wang
Chang-Liang
CL
Zhao
Wen-Hua
WH
Lv
Ming
M
Wang
Chun-Ying
CY
Zhong
Wei-Xia
WX
Zhou
Wu-Yuan
WY
Yu
Wen-Sheng
WS
Zhang
Yan
Y
Li
Sheng
S
D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001094:Arachidonate 5-Lipoxygenase / Q000235:genetics / Q000378:metabolism*; D002455:Cell Division / Q000187:drug effects; D051546:Cyclooxygenase 2 / Q000235:genetics; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use*; D005434:Flow Cytometry; D005663:Furans / Q000627:therapeutic use*; D005784:Gene Amplification; D006801:Humans; D016859:Lipoxygenase Inhibitors / Q000627:therapeutic use*; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D020133:Reverse Transcriptase Polymerase Chain Reaction
D052246:Cyclooxygenase 2 Inhibitors; D005663:Furans; D016859:Lipoxygenase Inhibitors; D001094:Arachidonate 5-Lipoxygenase; D051546:Cyclooxygenase 2